Kenvue, Inc. (KVUE)

Kenvue's stock price has been influenced by several events in the past six months, with the share price declining by 20.53% between April 7, 2025, and April 6, 2026. Kenvue announced mixed financial results for Q4 2025, beating revenue estimates but missing on diluted EPS, though adjusted EPS surpassed expectations. Analyst ratings saw downgrades and upgrades from various firms, with price objective adjustments. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close in the second half of 2026. As of April 10, 2026, Kenvue Inc.'s overall moving average trend leaned bearish.

Demand for certain Kenvue products exhibits seasonality, with seasonal demand for allergy and sun care products significantly impacted by weather patterns. Kenvue's gross margins are historically pressured in the fourth quarter due to maintenance costs.

Kenvue, Inc. is a global consumer health company spun off from Johnson & Johnson in May 2023, operating in the Consumer Defensive sector, specifically within the Household & Personal Products industry. The company focuses on self-care, skin health, and essential health categories, offering a diverse portfolio of well-known brands such as Tylenol, Aveeno and Listerine.

Kenvue has a significant global presence, with its brands sold in over 165 countries, connecting with approximately 1.2 billion people worldwide. Its operations span across North America, Asia Pacific (APAC), Europe, the Middle East, Africa (EMEA), and Latin America (LATAM). Approximately 50% of Kenvue's net sales in 2024 were generated outside of North America.

Kenvue's brand reputation in the past year has been impacted by several events. A group action lawsuit was filed against Kenvue in the UK over claims that its talc-based products cause cancer. Kenvue's shares traded lower following news that the Trump administration would release a report linking autism to acetaminophen use during pregnancy. Neutrogena recalled makeup wipes. The Skin Health and Beauty segment has faced significant sales declines and distribution challenges.

Institutional investors are the dominant shareholders in Kenvue, collectively owning a significant majority of the company's shares, including Vanguard Group Inc. and BlackRock, Inc. Johnson & Johnson, Kenvue's former parent company, was the largest individual Kenvue shareholder, owning 9.51% of the company after the spin-off, though they have strategically divested most of their stake. Individual insiders hold a much smaller percentage of shares.